KNSA Q2 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$157M+44.3% YoY

Gross Profit

$86M54.7% margin

Operating Income

$20M12.9% margin

Net Income

$18M11.4% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+13.8%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$28M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$661M

Total Liabilities

$166M

Stockholders' Equity

$495M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$157M	$109M	+44.3%
Gross Profit	$86M	$66M	+29.6%
Operating Income	$20M	-$117,000	+17330.8%
Net Income	$18M	-$4M	+556.3%

Revenue Segments

Product

$157M100%